Nestlé wagers $41M on Enterome's preclinical food allergy and IBD prospect

Nestlé Health Science has returned to the deal table once again, putting down 40 million euros ($41 million) to co-develop Enterome’s preclinical IL-10 inducer and collaborate on the discovery of other food allergy candidates.